Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis
- PMID: 20378598
- DOI: 10.1183/09031936.00166809
Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis
Abstract
Sarcoidosis is a systemic granulomatous disease with predominant manifestation in the lungs, often presenting as interstitial lung disease. Pulmonary function abnormalities in sarcoidosis include restriction of lung volumes, reduction in diffusing capacity of the lung for carbon monoxide (D(L,CO)), reduced static lung compliance (C(L,s)) and airway obstruction. The aim of the present study was to assess various lung function indices, including C(L,s) and D(L,CO), as markers of functional abnormality in sarcoidosis patients. Results from 830 consecutive patients referred for lung function tests with a diagnosis of sarcoidosis (223 in stage I, 486 in stage II and 121 in stage III) were retreospectively analysed. The mean ± sd age of the patients was 40 ± 11 yrs; 18% were active smokers and 24% were former smokers. Normal total lung capacity was found in 772 (93%) patients. Of these cases, 24.5% had a low C(L,s) and 21.5% had a low D(L,CO). At least one abnormality was observed in 39.3% of these patients, whereas, in restrictive patients, this figure was 88%. Airway obstruction was present in 11.7% of cases. Lung volumes usually remain within the normal range and measurement of either C(L,s) or D(L,CO) often reveal impaired lung function in sarcoidosis patients, even when their lung volumes are still in the normal range; these two measurements provide complementary information.
Similar articles
-
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.Mayo Clin Proc. 2007 Jan;82(1):48-54. doi: 10.4065/82.1.48. Mayo Clin Proc. 2007. PMID: 17285785
-
Lung mechanics and their relationship to lung volumes in pulmonary sarcoidosis.Eur Respir J. 1989 Jul;2(7):643-51. Eur Respir J. 1989. PMID: 2776871
-
Is it useful to perform carbon monoxide diffusion capacity and respiratory muscle function tests in patients with multiple sclerosis without disability?Respirology. 2012 Jul;17(5):869-75. doi: 10.1111/j.1440-1843.2012.02191.x. Respirology. 2012. PMID: 22564062
-
The pulmonary interstitium: an introductory review.Adv Exp Med Biol. 2003;536:141-5. doi: 10.1007/978-1-4419-9280-2_18. Adv Exp Med Biol. 2003. PMID: 14635660 Review. No abstract available.
-
Pulmonary function in sarcoidosis.Ohio State Med J. 1967 Dec;63(12):1589-93. Ohio State Med J. 1967. PMID: 4865405 Review. No abstract available.
Cited by
-
Assessment of lung function and severity grading in interstitial lung diseases (% predicted versus z-scores) and association with survival: A retrospective cohort study of 6,808 patients.PLoS Med. 2025 May 29;22(5):e1004619. doi: 10.1371/journal.pmed.1004619. eCollection 2025 May. PLoS Med. 2025. PMID: 40440426 Free PMC article.
-
Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.Respir Res. 2022 Jun 25;23(1):169. doi: 10.1186/s12931-022-02094-7. Respir Res. 2022. PMID: 35752806 Free PMC article.
-
Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis.Lung. 2012 Oct;190(5):529-36. doi: 10.1007/s00408-012-9406-8. Epub 2012 Jul 8. Lung. 2012. PMID: 22773249
-
Phenotypes and Endotypes in Sarcoidosis: Unraveling Prognosis and Disease Course.Biomedicines. 2025 Jan 24;13(2):287. doi: 10.3390/biomedicines13020287. Biomedicines. 2025. PMID: 40002701 Free PMC article. Review.
-
HO-1 protects smokers exposed to artificial stone dust for pulmonary function tests deterioration.Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):276-284. doi: 10.36141/svdld.v35i3.6968. Epub 2018 Apr 28. Sarcoidosis Vasc Diffuse Lung Dis. 2018. PMID: 32476913 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical